BXRX: Baudax Bio, Inc. - Summary | Jitta

Baudax Bio, Inc.

NASDAQ:BXRX

Notice
Stock data is unavailable or the company’s delisted.
Price
$0.00
Loss Chance
54.3%
2.47JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (34)
Recent Business Performance (53)
Financial Strength (34)
Return to Shareholders (16)
Competitive Advantage (36)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
2.47
100.00%
3.03
208.13%
3.05
162.56%
Pharmaceuticals
5.41
69.27%
5.05
81.56%
5.69
90.01%
COMPANY DESCRIPTION
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.